Arcturus Teams With CSL to Develop mRNA Vaccines
For $200 million up front and a possible $4.3 billion later, Arcturus Therapeutics has agreed to a vaccine collaboration with CSL Seqirus.
As part of the deal, Arcturus, a late-stage clinical mRNA medicines and vaccines company, will provide CSL Seqirus with a license to its self-amplifying mRNA technology along with mRNA drug substance and drug product manufacturing expertise.
CSL Seqirus will lead the development and commercialization of vaccines under the collaboration.
The partners aim to develop vaccines for COVID-19, influenza and three other globally prevalent respiratory infectious diseases.